US 12,435,322 B2
Therapeutic nuclease compositions and methods
Jeffrey A. Ledbetter, Seattle, WA (US); Martha Hayden-Ledbetter, Seattle, WA (US); Keith Elkon, Seattle, WA (US); and Xizhang Sun, Seattle, WA (US)
Assigned to University Of Washington, Seattle, WA (US)
Filed by University Of Washington Through Its Center For Commercialization, Seattle, WA (US)
Filed on Mar. 16, 2022, as Appl. No. 17/696,364.
Application 14/516,161 is a division of application No. 13/799,843, filed on Mar. 13, 2013, abandoned.
Application 13/799,843 is a division of application No. 13/197,731, filed on Aug. 3, 2011, granted, now 8,841,416, issued on Sep. 23, 2014.
Application 17/696,364 is a continuation of application No. 15/679,746, filed on Aug. 17, 2017, granted, now 11,306,297.
Application 15/679,746 is a continuation of application No. 14/516,161, filed on Oct. 16, 2014, granted, now 9,790,479, issued on Oct. 17, 2017.
Application 13/197,731 is a continuation of application No. PCT/US2010/055131, filed on Nov. 2, 2010.
Claims priority of provisional application 61/370,752, filed on Aug. 4, 2010.
Claims priority of provisional application 61/257,458, filed on Nov. 2, 2009.
Prior Publication US 2023/0057085 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/40 (2006.01); C07K 16/18 (2006.01); C12N 9/22 (2006.01); C12N 9/96 (2006.01); C12N 11/06 (2006.01); A61K 38/00 (2006.01); C07K 1/00 (2006.01)
CPC C12N 9/22 (2013.01) [C07K 16/18 (2013.01); C12N 9/96 (2013.01); C12N 11/06 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01); C12Y 301/27005 (2013.01); Y02P 20/582 (2015.11)] 22 Claims
 
1. A method for treating lupus nephritis in a subject in need thereof, comprising administering to the subject a composition comprising:
a polypeptide comprising human RNase 1 operatively coupled with or without a linker to the N-terminus of an Fc domain, and DNase operatively coupled with or without a linker to the C-terminus of the Fc domain, wherein the Fc domain is a human immunoglobulin Fc domain or a mutant human immunoglobulin Fc domain, and wherein the human immunoglobulin Fc domain or mutant human immunoglobulin Fc domain comprises at least one hinge region; and
a pharmaceutically acceptable carrier,
such that treatment occurs.